about
Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectivenessMore frequent, more costly? Health economic modelling aspects of monitoring glaucoma patients in EnglandCost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial.Effect of patient's life expectancy on the cost-effectiveness of treatment for ocular hypertensionLatanoprost versus timolol as first choice therapy in patients with ocular hypertension. A cost-effectiveness analysis.Giant cell arteritis: a review.Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK.The effectiveness of early lens extraction with intraocular lens implantation for the treatment of primary angle-closure glaucoma (EAGLE): study protocol for a randomized controlled trialConsequences of amblyopia on education, occupation, and long term vision lossIs it worthwhile to conduct a randomized controlled trial of glaucoma screening in the United Kingdom?The prevalence and causes of visual impairment in young Turkish menRecent trends in visual impairment and blindness in the UK.Early lens extraction with intraocular lens implantation for the treatment of primary angle closure glaucoma: an economic evaluation based on data from the EAGLE trial.The Cost of Blindness in the Republic of Ireland 2010-2020.Cost-effectiveness of latanoprost and timolol maleate for the treatment of glaucoma in Scandinavia and the United Kingdom, using a decision-analytic health economic model.Cost-effectiveness of ocriplasmin for the treatment of vitreomacular traction and macular holeEvaluating the Long-Term Cost-Effectiveness of Daily Administered GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes in the United Kingdom.Projected long-term outcomes in patients with type 1 diabetes treated with fast-acting insulin aspart vs conventional insulin aspart in the UK setting.Evaluation of the long-term cost-effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the UK setting.Modelling the cost-effectiveness of adopting risk-stratified approaches to extended screening intervals in the national diabetic retinopathy screening programme in Scotland.The Economic Impact of Blindness in Europe.Improving the cost-effectiveness of photographic screening for diabetic macular oedema: a prospective, multi-centre, UK study.Cost-effectiveness of early detection and treatment of ocular hypertension and primary open-angle glaucoma by the ophthalmologist.The calculation and use of economic burden dataA revolution in Welsh low vision service provision.An estimation of the worldwide economic and health burden of visual impairment.Updating diabetic retinopathy screening lists using automatic extraction from GP patient records.The economic impact of sight loss and blindness in the UK adult population.Using contrast sensitivity to estimate the cost-effectiveness of verteporfin in patients with predominantly classic age-related macular degeneration.Undergraduate ophthalmology education - A survey of UK medical schools.Personal costs of visual impairment by different eye diseases and severity of visual loss.
P2860
Q24674358-0942DEAF-CCEC-4E0D-8AFB-89CB43233C8FQ28597031-F631DDC4-4516-46C6-B355-316F168EFBAFQ31049802-94A7C763-DE2D-4570-B616-ED275A83C0C8Q33566458-ABFA422D-03B7-488D-8730-31F4B0BC230DQ33669278-F51DDC0B-9ABD-4397-9B03-83F3DC3AF244Q33688189-51796CD9-184C-4DA3-8E9F-271B4B3BC634Q33732593-F127792D-C996-4228-A64A-77C7456D7EA1Q33909132-D8BF2B30-184C-42C6-B0A2-88B2573E590BQ35592424-A9F60EB5-97DA-43D0-863A-3B08BEA79107Q35875638-BF43A12F-1E1D-40BF-9B7C-CF9AD7A13385Q36111109-1B40634B-A143-4973-87CB-414E9370833FQ36121422-D6E3035C-55DB-49C9-8CAD-C59E6FE780CEQ36249645-97A1D4DB-5423-48CD-987F-CB56506A2A55Q36627693-63A3BA7D-2A81-4D03-817E-C4E1D504997BQ36920000-FBF34902-CA68-4B1F-B7FC-A02774A59E73Q37037822-42B4584E-2E02-4E31-9007-92AAF4CE1AB2Q37639302-C2C88FFA-96D6-4F57-B527-6B192B1E12DAQ38675810-140F118C-9746-4794-9F97-36BE29CF87AFQ38765656-C8F26283-37BD-4A45-80A0-72A53CD666DCQ39867113-7A0FF22D-DBE9-48F6-9B58-97D0E6083D87Q40139689-5E2569F2-4E34-4329-A69C-760D50CA0774Q40180937-1AEA6D9B-35D2-40D7-8158-C1436CDDD5ECQ42604604-55F84927-EFBC-49D6-B527-8F065E6BA5DEQ42701616-57DCE226-00F1-4CE8-97DE-E158C2533A59Q43006960-D9E0A140-E212-42BC-BA66-8784EF389226Q44872122-6A27DD37-A56A-4D59-9D73-B983AAAAFB93Q45788661-CD4EE1FC-E29A-4DC1-BEBB-40FC8D82EB8CQ48139906-21D96C8E-400F-4B90-8840-A62A2A72B8D4Q50792115-6CD2B92F-ABA7-4641-B7B5-93DCF1244D80Q51053083-C1BFBF6C-3EB2-447F-88F2-4C3E3E5BF31FQ51123819-62C6FE92-295A-4547-BCBC-6225A90330EE
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
What is the cost of blindness?
@ast
What is the cost of blindness?
@en
type
label
What is the cost of blindness?
@ast
What is the cost of blindness?
@en
prefLabel
What is the cost of blindness?
@ast
What is the cost of blindness?
@en
P2860
P356
P1476
What is the cost of blindness?
@en
P2860
P304
P356
10.1136/BJO.87.10.1201
P407
P577
2003-10-01T00:00:00Z